What can we do about the delay of TDM-1

[schoonder]

Thanks Chrisy for pointing out that it was an AVERAGE of 7 prior treatments ranging from 3-13, subject post has been corrected.
Note of interest, compilation of T-DM1 data Genentech is looking at continuous to be promising and must have convinced them to broaden their attack on Her2-positive cancer. A new multinational trial in both adjuvant and neo-adjuvant settings is about to get underway, more details can be found in the clinicaltrials.gov registry.